Emapalumab – Uses, Dosage, Side Effects, Interaction Emapalumab (em” a pal’ ue mab) is a recombinant, human IgG1 monoclonal antibody to gamma interferon, which inhibits its binding to cell surface interferon receptors and the subsequent activation of intracellular proinflammatory signaling pathways. Gamma interferon levels are known to be elevated in patients with hemophagocytic lymphohistiocytosis (HLH), a life-threatening inflammatory syndrome marked by fever, enlargement of liver and spleen, macrophage update of red blood cells (hemophagocytosis) in bone marrow, spleen and lymph nodes, low natural killer cell activity and high levels of serum ferritin, triglycerides and multiple cytokines. Emapalumab is an interferon-gamma-blocking antibody used to treat primary hemophagocytic lymphohistiocytosis. Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon-gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi, and FDA-approved on November 20, 2018.[rx,rx] The approval of emapalumab was followed by the designation of an orphan drug, priority review, and breakthrough therapy.[rx] As well, emapalumab was given the status of PRIME by the EMA.[rx] Mechanism of action Emapalumab acts by binding and neutralizing interferon-gamma.[rx] The specific interaction between emapalumab and interferon-gamma produces an inhibition in the interaction between interferon-gamma and its cognate receptor on T-cells which produces the neutralizing activity.[rx] It is important to consider that emapalumab inhibits both free and IFNGR1-bound interferon-gamma as well as the interaction with IFNGR1 and IFNGR2 at the cell surface.[rx] HLH is an immune dysregulation syndrome in which several cytokines are involved but it has been reported that interferon-gamma plays a pivotal role in the development of this disease as studies have shown a vast increase in the interferon-gamma levels in HLH patients.[rx] In phase 2/3 clinical trials, emapalumab administered concomitantly with dexamethasone reported an overall response in 63% of the patients. The overall response was defined as the achievement of complete or partial response or HLH improvement.[rx] In this trial and as proof of interferon-gamma neutralization, there was registered a sharp decrease in serum CXCL9 and to avoid QT prolongation in the presence of low doses of emapalumab.[rx] Indications Emapalumab is indicated for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance to conventional HLH therapy.[rx] The HLH condition is a hyperinflammatory status characterized by the overwhelming activation of normal T lymphocytes and macrophages which can lead to disturbances in the hematology profile and even death. As part of the condition profile, there have been reports proving a massive overexpression of interferon-gamma which is thought to drive the immune hyperactivation leading to organ failure.[rx] This condition is usually developed and presents the symptomatic profile within the first months or years of life. These symptoms consist of fever, enlarged liver or spleen, and a lower number of blood cells.[rx] Progressive, refractory, primary intolerance with conventional therapy, recurrent Hemophagocytic Lymphohistiocytosis Emapalumab is used to treat primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy. For the treatment of primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy Use in Cancer Emapalumab-lzsg is approved to treat: Hemophagocytic lymphohistiocytosis (HLH) is inherited. It is used in adults and children (newborn and older) whose disease is refractory (does not respond to treatment), has recurred, has gotten worse, or cannot be treated with other therapies for HLH. Emapalumab-lzsg is also being studied in the treatment of other conditions. Contraindications active tuberculosis shingles a type of fungal lung infection called histoplasmosis an infection due to a fungus pneumonia with a fungus called Pneumocystis jirovecii Dosage Strengths: lzsg 5 mg/mL Histiocytosis Initial dose: 1 mg/kg IV over 1 hour 2 times a week (every 3 to 4 days) Doses after the initial dose may be increased stepwise to 10 mg/kg based on clinical and laboratory criteria (see Dose Adjustments). Duration of therapy: Until hematopoietic stem cell transplantation (HSCT) is performed or unacceptable toxicity; discontinue when a patient no longer requires treatment of HLH. Premedication/Concomitant Medication: For patients who are not receiving baseline dexamethasone: Begin dexamethasone at a daily dose of at least 5 to 10 mg/m2 the day before initiation of this drug. For patients who were receiving baseline dexamethasone: They may continue their regular dose provided the dose is at least 5 mg/m2. Dexamethasone can be tapered according to the judgment of the physician. Test for latent TB using the purified protein derivative (PPD) or IFNy release assay and evaluate patients for TB risk factors. Administer TB prophylaxis to patients at risk, or known to have a positive PPD test result or positive IFNy release assay. Administer prophylaxis for herpes zoster, Pneumocystis jirovecii, and fungal infections prior to therapy initiation. During therapy monitor for TB, adenovirus, EBV, and CMV every 2 weeks and as clinically indicated. Pediatric Dose for Histiocytosis Initial dose: 1 mg/kg IV over 1 hour 2 times a week (every 3 to 4 days) Doses after the initial dose may be increased stepwise to 10 mg/kg based on clinical and laboratory criteria (see Dose Adjustments). Duration of therapy: Until hematopoietic stem cell transplantation (HSCT) is performed or unacceptable toxicity; discontinue when a patient no longer requires treatment of HLH. Premedication/Concomitant Medication: For patients who are not receiving baseline dexamethasone: Begin dexamethasone at a daily dose of at least 5 to 10 mg/m2 the day before initiation of this drug. For patients who were receiving baseline dexamethasone: They may continue their regular dose provided the dose is at least 5 mg/m2. Dexamethasone can be tapered according to the judgment of the physician. Test for latent TB using the purified protein derivative (PPD) or IFNy release assay and evaluate patients for TB risk factors. Administer TB prophylaxis to patients at risk, or known to have a positive PPD test result or positive IFNy release assay. Administer prophylaxis for herpes zoster, Pneumocystis jirovecii, and fungal infections prior to therapy initiation. During therapy monitor for TB, adenovirus, EBV, and CMV every 2 weeks and as clinically indicated. Dose Adjustments Dose Modification Based on Response: Day 1: Starting dose of 1 IV mg/kg Increase the dose to 3 mg/kg IV on Day 3 for unsatisfactory improvement Increase the dose to 6 mg/kg IV on Day 6 onwards for unsatisfactory improvement Increase dose to 10 mg/kg IV from Day 9 onwards NOTE: UNSATISFACTORY IMPROVEMENT ON DAY 3 AND DAY 6 IS DEFINED AS ASSESSED BY A HEALTHCARE PROVIDER AND AT LEAST ONE OF THE FOLLOWING: FEVER: Persistent or recurring PLATELET COUNT: If the baseline is less than 50,000/mm3 and no improvement to greater than 50,000/mm3 If the baseline is greater than 50,000/mm3 and less than 30% improvement If the baseline is greater than 100,000/mm3 and decreases to less than 100,000/mm3 NEUTROPHIL COUNT: If the baseline is less than 500/mm3 and no improvement to greater than 500/mm3 If a baseline is greater than 500 to 1000/mm3 and decreases to less than 500/mm3 -If the baseline is 1000 to 1500/mm3 and decreases to less than 1000/ mm3 FERRITIN (ng/mL): If the baseline is 3000 ng/mL or greater and less than a 20% decrease If the baseline is less than 3000 ng/mL and any increase to greater than 3000 ng/mL SPLENOMEGALY: Any worsening COAGULOPATHY (both D-Dimer and Fibrinogen must apply): D-Dimer: If abnormal at baseline and no improvement Fibrinogen (mg/dL): If baseline levels are 100 mg/dL or less and no improvement If baseline levels are greater than 100 mg/dL) and any decrease to less than 100 mg/dL NOTE: UNSATISFACTORY IMPROVEMENT ON DAY 9 IS DEFINED AS: Assessment by a healthcare provider that based on initial signs of response, a further increase in the dose can be of benefit. Administration advice: Administer diluted solution IV over 1 hour through an IV line containing a sterile, non-pyrogenic, low-protein binding 0.2-micron in-line filter. Do not infuse this drug concomitantly with other agents and do not add any other product to the infusion bag or syringe. Side Effects The Most Common constipation nose bleeds fast, slow, or irregular heartbeat fast breathing muscle cramps numbness and tingling bloody or black, tarry stools vomiting blood or brown material that resembles coffee grounds decreased urination swelling in the hands, feet, ankles, or lower legs More common Agitation back pain black, tarry stools bloating or swelling of the face, arms, hands, lower legs, or feet bloody stools blurred vision chest pain, discomfort, or tightness chills confusion cough decreased awareness or responsiveness decreased urine depression difficult or labored breathing dry mouth fast, pounding, or irregular heartbeat or pulse feeling of warmth fever headache hoarseness hostility increased thirst irritability lightheadedness, dizziness, or fainting loss of appetite loss of consciousness lower back or side pain mood changes muscle pain, cramps, or twitching nausea nervousness nosebleed numbness or tingling in the hands, feet, or lips painful or difficult urination pounding in the ears rapid weight gain rapid, shallow breathing redness of the face, neck, arms and occasionally, upper chest seizures severe sleepiness slow heartbeat swollen glands unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness unusual weight gain or loss vomiting vomiting of blood or material that looks like coffee grounds Rare fever, chills, night sweats; loss of appetite, weight loss; feeling very tired; warmth, redness, or painful sores on your skin; cough, trouble breathing; mouth and throat ulcers; cough with bloody mucus; or any other new or worsening signs of infection. fever; or increased blood pressure. Drug Interaction DRUG INTERACTION Abatacept The risk or severity of adverse effects can be increased when Abatacept is combined with Emapalumab. Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Emapalumab. Abemaciclib The metabolism of Abemaciclib can be increased when combined with Emapalumab. Abrocitinib The metabolism of Abrocitinib can be increased when combined with Emapalumab. Acalabrutinib The metabolism of Acalabrutinib can be increased when combined with Emapalumab. Acebutolol The metabolism of Acebutolol can be increased when combined with Emapalumab. Acenocoumarol The metabolism of Acenocoumarol can be increased when combined with Emapalumab. Acetaminophen The metabolism of Acetaminophen can be increased when combined with Emapalumab. Acetohexamide The metabolism of Acetohexamide can be increased when combined with Emapalumab. Acetylsalicylic acid The metabolism of Acetylsalicylic acid can be increased when combined with Emapalumab. Acyclovir The metabolism of Acyclovir can be increased when combined with Emapalumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Emapalumab. Adenovirus type The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Emapalumab. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Emapalumab. Agomelatine The metabolism of Agomelatine can be increased when combined with Emapalumab. Albendazole The metabolism of Albendazole can be increased when combined with Emapalumab. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Emapalumab. Alectinib The metabolism of Alectinib can be increased when combined with Emapalumab. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Emapalumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Emapalumab. Alfentanil The metabolism of Alfentanil can be increased when combined with Emapalumab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Emapalumab. Allogeneic The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Emapalumab. Almotriptan The metabolism of Almotriptan can be increased when combined with Emapalumab. Alogliptin The metabolism of Alogliptin can be increased when combined with Emapalumab. Alosetron The metabolism of Alosetron can be increased when combined with Emapalumab. Alpelisib The metabolism of Alpelisib can be increased when combined with Emapalumab. Alprazolam The metabolism of Alprazolam can be increased when combined with Emapalumab. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Emapalumab. Ambrisentan The metabolism of Ambrisentan can be increased when combined with Emapalumab. Aminophenazone The metabolism of Aminophenazone can be increased when combined with Emapalumab. Aminophylline The metabolism of Aminophylline can be increased when combined with Emapalumab. Amiodarone The metabolism of Amiodarone can be increased when combined with Emapalumab. Amitriptyline The metabolism of Amitriptyline can be increased when combined with Emapalumab. Amivantamab The risk or severity of adverse effects can be increased when Emapalumab is combined with Amivantamab. Amodiaquine The metabolism of Amodiaquine can be increased when combined with Emapalumab. Amoxapine The metabolism of Amoxapine can be increased when combined with Emapalumab. Amphetamine The metabolism of Amphetamine can be increased when combined with Emapalumab. Amprenavir The metabolism of Amprenavir can be increased when combined with Emapalumab. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Emapalumab. Anagrelide The metabolism of Anagrelide can be increased when combined with Emapalumab. Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Emapalumab. Anastrozole The metabolism of Anastrozole can be increased when combined with Emapalumab. Anifrolumab The risk or severity of adverse effects can be increased when Anifrolumab is combined with Emapalumab. Ansuvimab The risk or severity of adverse effects can be increased when Emapalumab is combined with Ansuvimab. Anthrax immune The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Emapalumab. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Emapalumab. Antilymphocyte The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Emapalumab. Antipyrine The metabolism of Antipyrine can be increased when combined with Emapalumab. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Emapalumab. Apalutamide The metabolism of Apalutamide can be increased when combined with Emapalumab. Apixaban The metabolism of Apixaban can be increased when combined with Emapalumab. Apomorphine The metabolism of Apomorphine can be increased when combined with Emapalumab. Apremilast The metabolism of Apremilast can be increased when combined with Emapalumab. Aprepitant The metabolism of Aprepitant can be increased when combined with Emapalumab. Arformoterol The metabolism of Arformoterol can be increased when combined with Emapalumab. Aripiprazole The metabolism of Aripiprazole can be increased when combined with Emapalumab. Aripiprazole The metabolism of Aripiprazole lauroxil can be increased when combined with Emapalumab. Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Emapalumab. Artemether The metabolism of Artemether can be increased when combined with Emapalumab. Asenapine The metabolism of Asenapine can be increased when combined with Emapalumab. Asfotase alfa The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Emapalumab. Astemizole The metabolism of Astemizole can be increased when combined with Emapalumab. COVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Emapalumab. Asunaprevir The metabolism of Asunaprevir can be increased when combined with Emapalumab. Atazanavir The metabolism of Atazanavir can be increased when combined with Emapalumab. Atenolol The metabolism of Atenolol can be increased when combined with Emapalumab. Atezolizumab The risk or severity of adverse effects can be increased when Atezolizumab is combined with Emapalumab. Atoltivimab The risk or severity of adverse effects can be increased when Emapalumab is combined with Atoltivimab. Atomoxetine The metabolism of Atomoxetine can be increased when combined with Emapalumab. Atorvastatin The metabolism of Atorvastatin can be increased when combined with Emapalumab. Avanafil The metabolism of Avanafil can be increased when combined with Emapalumab. Avapritinib The metabolism of Avapritinib can be increased when combined with Emapalumab. Avelumab The risk or severity of adverse effects can be increased when Avelumab is combined with Emapalumab. Axitinib The metabolism of Axitinib can be increased when combined with Emapalumab. Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Emapalumab. Azathioprine The metabolism of Azathioprine can be increased when combined with Emapalumab. Azelastine The metabolism of Azelastine can be increased when combined with Emapalumab. Azithromycin The metabolism of Azithromycin can be increased when combined with Emapalumab. Bacillus antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Emapalumab. Bacillus The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Emapalumab. Bacillus antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Emapalumab. Bamlanivimab The risk or severity of adverse effects can be increased when Emapalumab is combined with Bamlanivimab. Baricitinib The risk or severity of adverse effects can be increased when Baricitinib is combined with Emapalumab. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Emapalumab. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Emapalumab. Bebtelovimab The risk or severity of adverse effects can be increased when Emapalumab is combined with Bebtelovimab. Beclomethasone The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Emapalumab. Belantamab The risk or severity of adverse effects can be increased when Emapalumab is combined with Belantamab mafodotin. Belatacept The risk or severity of adverse effects can be increased when Belatacept is combined with Emapalumab. Belimumab The risk or severity of adverse effects can be increased when Belimumab is combined with Emapalumab. Belinostat The risk or severity of adverse effects can be increased when Belinostat is combined with Emapalumab. Belumosudil The risk or severity of adverse effects can be increased when Emapalumab is combined with Belumosudil. Belzutifan The metabolism of Belzutifan can be increased when combined with Emapalumab. Bendamustine The metabolism of Bendamustine can be increased when combined with Emapalumab. Benralizumab The risk or severity of adverse effects can be increased when Benralizumab is combined with Emapalumab. Benzatropine The metabolism of Benzatropine can be increased when combined with Emapalumab. Benzocaine The metabolism of Benzocaine can be increased when combined with Emapalumab. Benzphetamine The metabolism of Benzphetamine can be increased when combined with Emapalumab. Benzyl alcohol The metabolism of Benzyl alcohol can be increased when combined with Emapalumab. Bepridil The metabolism of Bepridil can be increased when combined with Emapalumab. Besilesomab The risk or severity of adverse effects can be increased when Besilesomab is combined with Emapalumab. Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Emapalumab. Betaxolol The metabolism of Betaxolol can be increased when combined with Emapalumab. Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Emapalumab. Bexarotene The metabolism of Bexarotene can be increased when combined with Emapalumab. Bezlotoxumab The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Emapalumab. Bicalutamide The metabolism of Bicalutamide can be increased when combined with Emapalumab. Bimekizumab The risk or severity of adverse effects can be increased when Bimekizumab is combined with Emapalumab. Binimetinib The metabolism of Binimetinib can be increased when combined with Emapalumab. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Emapalumab. Blinatumomab The risk or severity of adverse effects can be increased when Blinatumomab is combined with Emapalumab. Boceprevir The metabolism of Boceprevir can be increased when combined with Emapalumab. Bordetella The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Emapalumab. Bortezomib The metabolism of Bortezomib can be increased when combined with Emapalumab. Bosentan The metabolism of Bosentan can be increased when combined with Emapalumab. Bosutinib The metabolism of Bosutinib can be increased when combined with Emapalumab. Brentuximab The metabolism of Brentuximab vedotin can be increased when combined with Emapalumab. Brexpiprazole The metabolism of Brexpiprazole can be increased when combined with Emapalumab. Brigatinib The metabolism of Brigatinib can be increased when combined with Emapalumab. Brivaracetam The metabolism of Brivaracetam can be increased when combined with Emapalumab. Brodalumab The risk or severity of adverse effects can be increased when Brodalumab is combined with Emapalumab. Brolucizumab The risk or severity of adverse effects can be increased when Emapalumab is combined with Brolucizumab. Bromazepam The metabolism of Bromazepam can be increased when combined with Emapalumab. Bromotheophylline The metabolism of Bromotheophylline can be increased when combined with Emapalumab. Brompheniramine The metabolism of Brompheniramine can be increased when combined with Emapalumab. Budesonide The risk or severity of adverse effects can be increased when Budesonide is combined with Emapalumab. Bupivacaine The metabolism of Bupivacaine can be increased when combined with Emapalumab. Buprenorphine The metabolism of Buprenorphine can be increased when combined with Emapalumab. Bupropion The metabolism of Bupropion can be increased when combined with Emapalumab. Burosumab The risk or severity of adverse effects can be increased when Burosumab is combined with Emapalumab. Buspirone The metabolism of Buspirone can be increased when combined with Emapalumab. Busulfan The metabolism of Busulfan can be increased when combined with Emapalumab. Cabazitaxel The metabolism of Cabazitaxel can be increased when combined with Emapalumab. Cabergoline The metabolism of Cabergoline can be increased when combined with Emapalumab. Cabozantinib The metabolism of Cabozantinib can be increased when combined with Emapalumab. Caffeine The metabolism of Caffeine can be increased when combined with Emapalumab. Canakinumab The risk or severity of adverse effects can be increased when Canakinumab is combined with Emapalumab. Candesartan cilexetil The metabolism of Candesartan cilexetil can be increased when combined with Emapalumab. Cannabidiol The metabolism of Cannabidiol can be increased when combined with Emapalumab. Capecitabine The metabolism of Capecitabine can be increased when combined with Emapalumab. Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Emapalumab. Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Emapalumab. Capsaicin The metabolism of Capsaicin can be increased when combined with Emapalumab. Carbamazepine The metabolism of Carbamazepine can be increased when combined with Emapalumab. Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Emapalumab. Carfilzomib The risk or severity of adverse effects can be increased when Carfilzomib is combined with Emapalumab. Carisoprodol The metabolism of Carisoprodol can be increased when combined with Emapalumab. Carmustine The metabolism of Carmustine can be increased when combined with Emapalumab. Carvedilol The metabolism of Carvedilol can be increased when combined with Emapalumab. Casirivimab The risk or severity of adverse effects can be increased when Emapalumab is combined with Casirivimab. Catumaxomab The risk or severity of adverse effects can be increased when Catumaxomab is combined with Emapalumab. Celecoxib The metabolism of Celecoxib can be increased when combined with Emapalumab. Celiprolol The metabolism of Celiprolol can be increased when combined with Emapalumab. Cemiplimab The risk or severity of adverse effects can be increased when Cemiplimab is combined with Emapalumab. Cenobamate The metabolism of Cenobamate can be increased when combined with Emapalumab. Cephalexin The metabolism of Cephalexin can be increased when combined with Emapalumab. Ceritinib The metabolism of Ceritinib can be increased when combined with Emapalumab. Cerivastatin The metabolism of Cerivastatin can be increased when combined with Emapalumab. Certolizumab pegol The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Emapalumab. Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Emapalumab. Cevimeline The metabolism of Cevimeline can be increased when combined with Emapalumab. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Emapalumab. Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Emapalumab. Chloroquine The metabolism of Chloroquine can be increased when combined with Emapalumab. Chlorpheniramine The metabolism of Chlorpheniramine can be increased when combined with Emapalumab. Chlorpromazine The metabolism of Chlorpromazine can be increased when combined with Emapalumab. Chlorpropamide The metabolism of Chlorpropamide can be increased when combined with Emapalumab. Chlorzoxazone The metabolism of Chlorzoxazone can be increased when combined with Emapalumab. Ciclesonide The metabolism of Ciclesonide can be increased when combined with Emapalumab. Cilgavimab The risk or severity of adverse effects can be increased when Emapalumab is combined with Cilgavimab. Cilostazol The metabolism of Cilostazol can be increased when combined with Emapalumab. Cinacalcet The metabolism of Cinacalcet can be increased when combined with Emapalumab. Cinnarizine The metabolism of Cinnarizine can be increased when combined with Emapalumab. Cisapride The metabolism of Cisapride can be increased when combined with Emapalumab. Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Emapalumab. Citalopram The metabolism of Citalopram can be increased when combined with Emapalumab. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Emapalumab. Clarithromycin The metabolism of Clarithromycin can be increased when combined with Emapalumab. Clevidipine The metabolism of Clevidipine can be increased when combined with Emapalumab. Clindamycin The metabolism of Clindamycin can be increased when combined with Emapalumab. Clobazam The metabolism of Clobazam can be increased when combined with Emapalumab. Clobetasol The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Emapalumab. Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Emapalumab. Clomipramine The metabolism of Clomipramine can be increased when combined with Emapalumab. Clonidine The metabolism of Clonidine can be increased when combined with Emapalumab. Clopidogrel The metabolism of Clopidogrel can be increased when combined with Emapalumab. Clostridium The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Emapalumab. Clotiazepam The metabolism of Clotiazepam can be increased when combined with Emapalumab. Clozapine The metabolism of Clozapine can be increased when combined with Emapalumab. Cobicistat The metabolism of Cobicistat can be increased when combined with Emapalumab. Cobimetinib The metabolism of Cobimetinib can be increased when combined with Emapalumab. Codeine The metabolism of Codeine can be increased when combined with Emapalumab. Conivaptan The metabolism of Conivaptan can be increased when combined with Emapalumab. Conjugated estrogens The metabolism of Conjugated estrogens can be increased when combined with Emapalumab. Copanlisib The metabolism of Copanlisib can be increased when combined with Emapalumab. Corticotropin The risk or severity of adverse effects can be increased when Corticotropin is combined with Emapalumab. Cortisone acetate The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Emapalumab. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Emapalumab. Crizotinib The metabolism of Crizotinib can be increased when combined with Emapalumab Cyclobenzaprine The metabolism of Cyclobenzaprine can be increased when combined with Emapalumab. Cyclophosphamide The metabolism of Cyclophosphamide can be increased when combined with Emapalumab. Cyclosporine Emapalumab may increase the immunosuppressive activities of Cyclosporine. Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Emapalumab. Dabrafenib The metabolism of Dabrafenib can be increased when combined with Emapalumab. Dacarbazine The metabolism of Dacarbazine can be increased when combined with Emapalumab. Daclatasvir The metabolism of Daclatasvir can be increased when combined with Emapalumab. Dacomitinib The metabolism of Dacomitinib can be increased when combined with Emapalumab. Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Emapalumab. Dapagliflozin The metabolism of Dapagliflozin can be increased when combined with Emapalumab. Dapsone The metabolism of Dapsone can be increased when combined with Emapalumab. Daratumumab The risk or severity of adverse effects can be increased when Daratumumab is combined with Emapalumab. Darifenacin The metabolism of Darifenacin can be increased when combined with Emapalumab. Dasabuvir The metabolism of Dasabuvir can be increased when combined with Emapalumab. Dasatinib The metabolism of Dasatinib can be increased when combined with Emapalumab. Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Emapalumab. Debrisoquine The metabolism of Debrisoquine can be increased when combined with Emapalumab. Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Emapalumab. Deflazacort The risk or severity of adverse effects can be increased when Deflazacort is combined with Emapalumab. Delavirdine The metabolism of Delavirdine can be increased when combined with Emapalumab. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Emapalumab. Desipramine The metabolism of Desipramine can be increased when combined with Emapalumab. Desogestrel The metabolism of Desogestrel can be increased when combined with Emapalumab. Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Emapalumab. Deucravacitinib The risk or severity of adverse effects can be increased when Emapalumab is combined with Deucravacitinib. Deutetrabenazine The metabolism of Deutetrabenazine can be increased when combined with Emapalumab. Dexamethasone The metabolism of Dexamethasone can be increased when combined with Emapalumab. Dexamethasone The metabolism of Dexamethasone acetate can be increased when combined with Emapalumab. Dexchlorpheniramin The metabolism of Dexchlorpheniramine maleate can be increased when combined with Emapalumab. Dexfenfluramine The metabolism of Dexfenfluramine can be increased when combined with Emapalumab. Dexibuprofen The metabolism of Dexibuprofen can be increased when combined with Emapalumab. Dexlansoprazole The metabolism of Dexlansoprazole can be increased when combined with Emapalumab. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Emapalumab. Dextroamphetamine The metabolism of Dextroamphetamine can be increased when combined with Emapalumab. Dextromethorphan The metabolism of Dextromethorphan can be increased when combined with Emapalumab. Dextropropoxyphene The metabolism of Dextropropoxyphene can be increased when combined with Emapalumab. Diazepam The metabolism of Diazepam can be increased when combined with Emapalumab. Diclofenac The metabolism of Diclofenac can be increased when combined with Emapalumab. Dicoumarol The metabolism of Dicoumarol can be increased when combined with Emapalumab. Dienestrol Dienestrol may increase the thrombogenic activities of Emapalumab. Diethylstilbestrol The metabolism of Diethylstilbestrol can be increased when combined with Emapalumab. Difluocortolone The risk or severity of adverse effects can be increased when Difluocortolone is combined with Emapalumab. Digitoxin The metabolism of Digitoxin can be increased when combined with Emapalumab. Digoxin Immune The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Emapalumab. Dihydralazine The metabolism of Dihydralazine can be increased when combined with Emapalumab. Dihydrocodeine The metabolism of Dihydrocodeine can be increased when combined with Emapalumab. Dihydroergocornine The metabolism of Dihydroergocornine can be increased when combined with Emapalumab. Dihydroergocristine The metabolism of Dihydroergocristine can be increased when combined with Emapalumab. Dihydroergotamine The metabolism of Dihydroergotamine can be increased when combined with Emapalumab. Diltiazem The metabolism of Diltiazem can be increased when combined with Emapalumab. Dimethyl fumarate The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Emapalumab. Dinutuximab The risk or severity of adverse effects can be increased when Dinutuximab is combined with Emapalumab. Diphenhydramine The metabolism of Diphenhydramine can be increased when combined with Emapalumab. Diroximel The risk or severity of adverse effects can be increased when Emapalumab is combined with Diroximel fumarate. Disopyramide The metabolism of Disopyramide can be increased when combined with Emapalumab. Disulfiram The metabolism of Disulfiram can be increased when combined with Emapalumab. Docetaxel The metabolism of Docetaxel can be increased when combined with Emapalumab. Doconexent The metabolism of Doconexent can be increased when combined with Emapalumab. Dofetilide The metabolism of Dofetilide can be increased when combined with Emapalumab. Dolasetron The metabolism of Dolasetron can be increased when combined with Emapalumab. Domperidone The metabolism of Domperidone can be increased when combined with Emapalumab. Donepezil The metabolism of Donepezil can be increased when combined with Emapalumab. Doravirine The metabolism of Doravirine can be increased when combined with Emapalumab. Dostarlimab The risk or severity of adverse effects can be increased when Emapalumab is combined with Dostarlimab. Dosulepin The metabolism of Dosulepin can be increased when combined with Emapalumab. Doxazosin The metabolism of Doxazosin can be increased when combined with Emapalumab. Doxepin The metabolism of Doxepin can be increased when combined with Emapalumab. Doxorubicin The metabolism of Doxorubicin can be increased when combined with Emapalumab. Dronabinol The metabolism of Dronabinol can be increased when combined with Emapalumab. Dronedarone The metabolism of Dronedarone can be increased when combined with Emapalumab. Drospirenone The metabolism of Drospirenone can be increased when combined with Emapalumab. Dulaglutide The risk or severity of adverse effects can be increased when Dulaglutide is combined with Emapalumab. Duloxetine The metabolism of Duloxetine can be increased when combined with Emapalumab. Dupilumab The risk or severity of adverse effects can be increased when Dupilumab is combined with Emapalumab. Durvalumab The risk or severity of adverse effects can be increased when Durvalumab is combined with Emapalumab. Dutasteride The metabolism of Dutasteride can be increased when combined with Emapalumab. Duvelisib The metabolism of Duvelisib can be increased when combined with Emapalumab. Ebastine The metabolism of Ebastine can be increased when combined with Emapalumab. Ebola Zaire The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Emapalumab. Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Emapalumab. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Emapalumab. Efavirenz The metabolism of Efavirenz can be increased when combined with Emapalumab. Eflapegrastim The risk or severity of adverse effects can be increased when Emapalumab is combined with Eflapegrastim. Eftrenonacog alfa The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Emapalumab. Elagolix The metabolism of Elagolix can be increased when combined with Emapalumab. Elbasvir The metabolism of Elbasvir can be increased when combined with Emapalumab. Eletriptan The metabolism of Eletriptan can be increased when combined with Emapalumab. Elexacaftor The metabolism of Elexacaftor can be increased when combined with Emapalumab. Eliglustat The metabolism of Eliglustat can be increased when combined with Emapalumab. Elotuzumab The risk or severity of adverse effects can be increased when Elotuzumab is combined with Emapalumab. Eltrombopag The metabolism of Eltrombopag can be increased when combined with Emapalumab. Emicizumab The risk or severity of adverse effects can be increased when Emicizumab is combined with Emapalumab. Enasidenib The metabolism of Enasidenib can be increased when combined with Emapalumab. Encainide The metabolism of Encainide can be increased when combined with Emapalumab. Encorafenib The metabolism of Encorafenib can be increased when combined with Emapalumab. Enflurane The metabolism of Enflurane can be increased when combined with Emapalumab. Entecavir The metabolism of Entecavir can be increased when combined with Emapalumab. Entrectinib The metabolism of Entrectinib can be increased when combined with Emapalumab. Enzalutamide The metabolism of Enzalutamide can be increased when combined with Emapalumab. Epinastine The metabolism of Epinastine can be increased when combined with Emapalumab. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Emapalumab. Eplerenone The metabolism of Eplerenone can be increased when combined with Emapalumab. Eptinezumab The risk or severity of adverse effects can be increased when Eptinezumab is combined with Emapalumab. Erdafitinib The metabolism of Erdafitinib can be increased when combined with Emapalumab. Erenumab The risk or severity of adverse effects can be increased when Erenumab is combined with Emapalumab. Ergotamine The metabolism of Ergotamine can be increased when combined with Emapalumab. Eribulin The risk or severity of adverse effects can be increased when Eribulin is combined with Emapalumab. Erlotinib The metabolism of Erlotinib can be increased when combined with Emapalumab. Erythromycin The metabolism of Erythromycin can be increased when combined with Emapalumab. Escitalopram The metabolism of Escitalopram can be increased when combined with Emapalumab. Esketamine The metabolism of Esketamine can be increased when combined with Emapalumab. Esmolol The metabolism of Esmolol can be increased when combined with Emapalumab. Esomeprazole The metabolism of Esomeprazole can be increased when combined with Emapalumab. Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Emapalumab. Estetrol The metabolism of Estetrol can be increased when combined with Emapalumab. Estradiol The metabolism of Estradiol can be increased when combined with Emapalumab. Estradiol acetate The metabolism of Estradiol acetate can be increased when combined with Emapalumab. Estradiol benzoate The metabolism of Estradiol benzoate can be increased when combined with Emapalumab. Estradiol cypionate The metabolism of Estradiol cypionate can be increased when combined with Emapalumab. Estradiol dienanthate The metabolism of Estradiol dienanthate can be increased when combined with Emapalumab. Estradiol valerate The metabolism of Estradiol valerate can be increased when combined with Emapalumab. Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Emapalumab. Estriol Estriol may increase the thrombogenic activities of Emapalumab. Estrone Estrone may increase the thrombogenic activities of Emapalumab. Estrone sulfate The metabolism of Estrone sulfate can be increased when combined with Emapalumab. Eszopiclone The metabolism of Eszopiclone can be increased when combined with Emapalumab. Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Emapalumab. Ethanol The metabolism of Ethanol can be increased when combined with Emapalumab. Ethinylestradiol The metabolism of Ethinylestradiol can be increased when combined with Emapalumab. Ethosuximide The metabolism of Ethosuximide can be increased when combined with Emapalumab. Etodolac The metabolism of Etodolac can be increased when combined with Emapalumab. Etoposide The metabolism of Etoposide can be increased when combined with Emapalumab. Etoricoxib The metabolism of Etoricoxib can be increased when combined with Emapalumab. Etravirine The metabolism of Etravirine can be increased when combined with Emapalumab. Everolimus The metabolism of Everolimus can be increased when combined with Emapalumab. Evolocumab The risk or severity of adverse effects can be increased when Evolocumab is combined with Emapalumab. Famtozinameran The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Emapalumab. Fanolesomab The risk or severity of adverse effects can be increased when Fanolesomab is combined with Emapalumab. Fedratinib The metabolism of Fedratinib can be increased when combined with Emapalumab. Felbamate The metabolism of Felbamate can be increased when combined with Emapalumab. Felodipine The metabolism of Felodipine can be increased when combined with Emapalumab. Fenfluramine The metabolism of Fenfluramine can be increased when combined with Emapalumab. Fenofibrate The metabolism of Fenofibrate can be increased when combined with Emapalumab. Fentanyl The metabolism of Fentanyl can be increased when combined with Emapalumab. Fesoterodine The metabolism of Fesoterodine can be increased when combined with Emapalumab. Fexinidazole The metabolism of Fexinidazole can be increased when combined with Emapalumab. Filgotinib The risk or severity of adverse effects can be increased when Emapalumab is combined with Filgotinib. Finasteride The metabolism of Finasteride can be increased when combined with Emapalumab. Finerenone The metabolism of Finerenone can be increased when combined with Emapalumab. Fingolimod Emapalumab may increase the immunosuppressive activities of Fingolimod. Flecainide The metabolism of Flecainide can be increased when combined with Emapalumab. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Emapalumab. Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Emapalumab. Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Emapalumab. Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Emapalumab. Fluindione The metabolism of Fluindione can be increased when combined with Emapalumab. Flunarizine The metabolism of Flunarizine can be increased when combined with Emapalumab. Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Emapalumab. Flunitrazepam The metabolism of Flunitrazepam can be increased when combined with Emapalumab. Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Emapalumab. Fluocinonide The risk or severity of adverse effects can be increased when Fluocinonide is combined with Emapalumab. Fluocortolone The risk or severity of adverse effects can be increased when Fluocortolone is combined with Emapalumab. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Emapalumab. Fluorouracil The metabolism of Fluorouracil can be increased when combined with Emapalumab. Fluoxetine The metabolism of Fluoxetine can be increased when combined with Emapalumab. Fluprednisolone The risk or severity of adverse effects can be increased when Fluprednisolone is combined with Emapalumab. Flurazepam The metabolism of Flurazepam can be increased when combined with Emapalumab. Flurbiprofen The metabolism of Flurbiprofen can be increased when combined with Emapalumab. Flutamide The metabolism of Flutamide can be increased when combined with Emapalumab. Fluticasone The metabolism of Fluticasone can be increased when combined with Emapalumab. Fluticasone The metabolism of Fluticasone furoate can be increased when combined with Emapalumab. Fluticasone propionate The metabolism of Fluticasone propionate can be increased when combined with Emapalumab. Fluvastatin The metabolism of Fluvastatin can be increased when combined with Emapalumab. Fluvoxamine The metabolism of Fluvoxamine can be increased when combined with Emapalumab. Formoterol The metabolism of Formoterol can be increased when combined with Emapalumab. Fosaprepitant The metabolism of Fosaprepitant can be increased when combined with Emapalumab. Fosphenytoin The metabolism of Fosphenytoin can be increased when combined with Emapalumab. Fremanezumab The risk or severity of adverse effects can be increased when Fremanezumab is combined with Emapalumab. Frovatriptan The metabolism of Frovatriptan can be increased when combined with Emapalumab. Fusidic acid The metabolism of Fusidic acid can be increased when combined with Emapalumab. Galantamine The metabolism of Galantamine can be increased when combined with Emapalumab. Galcanezumab The risk or severity of adverse effects can be increased when Galcanezumab is combined with Emapalumab. Gallium nitrate The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Emapalumab. Gefitinib The metabolism of Gefitinib can be increased when combined with Emapalumab. Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Emapalumab. Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Emapalumab. Gilteritinib The metabolism of Gilteritinib can be increased when combined with Emapalumab. Glasdegib The metabolism of Glasdegib can be increased when combined with Emapalumab. Glatiramer The risk or severity of adverse effects can be increased when Glatiramer is combined with Emapalumab. Gliclazide The metabolism of Gliclazide can be increased when combined with Emapalumab. Glimepiride The metabolism of Glimepiride can be increased when combined with Emapalumab. Glipizide The metabolism of Glipizide can be increased when combined with Emapalumab. Gliquidone The metabolism of Gliquidone can be increased when combined with Emapalumab. Glyburide The metabolism of Glyburide can be increased when combined with Emapalumab. Golimumab The risk or severity of adverse effects can be increased when Golimumab is combined with Emapalumab. Grepafloxacin The metabolism of Grepafloxacin can be increased when combined with Emapalumab. Guanabenz The metabolism of Guanabenz can be increased when combined with Emapalumab. Guselkumab The risk or severity of adverse effects can be increased when Guselkumab is combined with Emapalumab. Haemophilus The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Emapalumab. Halofantrine The metabolism of Halofantrine can be increased when combined with Emapalumab. Hydrocodone The metabolism of Hydrocodone can be increased when combined with Emapalumab. Hydrocortisone The metabolism of Hydrocortisone can be increased when combined with Emapalumab. Hydrocortisone The metabolism of Hydrocortisone acetate can be increased when combined with Emapalumab. Hydrocortisone The metabolism of Hydrocortisone butyrate can be increased when combined with Emapalumab. Hydrocortisone The metabolism of Hydrocortisone cypionate can be increased when combined with Emapalumab. Hydrocortisone The metabolism of Hydrocortisone phosphate can be increased when combined with Emapalumab. Hydrocortisone The risk or severity of adverse effects can be increased when Hydrocortisone succinate is combined with Emapalumab. Hydromorphone The metabolism of Hydromorphone can be increased when combined with Emapalumab. Hydroxychloroquine The metabolism of Hydroxychloroquine can be increased when combined with Emapalumab. Hydroxyprogester The metabolism of Hydroxyprogesterone caproate can be increased when combined with Emapalumab. Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Emapalumab. Hydroxyzine The metabolism of Hydroxyzine can be increased when combined with Emapalumab. Ibalizumab The risk or severity of adverse effects can be increased when Ibalizumab is combined with Emapalumab. Ibritumomab The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Emapalumab. Ibrutinib The metabolism of Ibrutinib can be increased when combined with Emapalumab. Ibuprofen The metabolism of Ibuprofen can be increased when combined with Emapalumab. Idarubicin The metabolism of Idarubicin can be increased when combined with Emapalumab. Idarucizumab The risk or severity of adverse effects can be increased when Idarucizumab is combined with Emapalumab. Idelalisib The metabolism of Idelalisib can be increased when combined with Emapalumab. Ifosfamide The metabolism of Ifosfamide can be increased when combined with Emapalumab. Iloperidone The metabolism of Iloperidone can be increased when combined with Emapalumab. Imatinib The metabolism of Imatinib can be increased when combined with Emapalumab. Imdevimab The risk or severity of adverse effects can be increased when Emapalumab is combined with Imdevimab. Imipramine The metabolism of Imipramine can be increased when combined with Emapalumab. Imlifidase The therapeutic efficacy of Emapalumab can be decreased when used in combination with Imlifidase. Indinavir The metabolism of Indinavir can be increased when combined with Emapalumab. Indomethacin The metabolism of Indomethacin can be increased when combined with Emapalumab. Inebilizumab The risk or severity of infection can be increased when Emapalumab is combined with Inebilizumab. Infigratinib The metabolism of Infigratinib can be increased when combined with Emapalumab. Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Emapalumab. Ketorolac The metabolism of Ketorolac can be increased when combined with Emapalumab. Labetalol The metabolism of Labetalol can be increased when combined with Emapalumab. Lacosamide The metabolism of Lacosamide can be increased when combined with Emapalumab. Lanadelumab The risk or severity of adverse effects can be increased when Lanadelumab is combined with Emapalumab. Lansoprazole The metabolism of Lansoprazole can be increased when combined with Emapalumab. Lapatinib The metabolism of Lapatinib can be increased when combined with Emapalumab. Lefamulin The metabolism of Lefamulin can be increased when combined with Emapalumab. Leflunomide The risk or severity of adverse effects can be increased when Emapalumab is combined with Leflunomide. Lemborexant The metabolism of Lemborexant can be increased when combined with Emapalumab. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Emapalumab. Lercanidipine The metabolism of Lercanidipine can be increased when combined with Emapalumab. Lesinurad The metabolism of Lesinurad can be increased when combined with Emapalumab. Letermovir The metabolism of Letermovir can be increased when combined with Emapalumab. Letrozole The metabolism of Letrozole can be increased when combined with Emapalumab. Levacetylmethadol The metabolism of Levacetylmethadol can be increased when combined with Emapalumab. Levamlodipine The metabolism of Levamlodipine can be increased when combined with Emapalumab. Levobetaxolol The metabolism of Levobetaxolol can be increased when combined with Emapalumab. Levobupivacaine The metabolism of Levobupivacaine can be increased when combined with Emapalumab. Levomilnacipran The metabolism of Levomilnacipran can be increased when combined with Emapalumab. Levonorgestrel The metabolism of Levonorgestrel can be increased when combined with Emapalumab. Lidocaine The metabolism of Lidocaine can be increased when combined with Emapalumab. Linagliptin The metabolism of Linagliptin can be increased when combined with Emapalumab. Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Emapalumab. Lisuride The metabolism of Lisuride can be increased when combined with Emapalumab. Lofexidine The metabolism of Lofexidine can be increased when combined with Emapalumab. Lomefloxacin The metabolism of Lomefloxacin can be increased when combined with Emapalumab. Lomitapide The metabolism of Lomitapide can be increased when combined with Emapalumab. Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Emapalumab. Lonafarnib The metabolism of Lonafarnib can be increased when combined with Emapalumab. Loncastuximab The risk or severity of adverse effects can be increased when Emapalumab is combined with Loncastuximab tesirine. Loperamide The metabolism of Loperamide can be increased when combined with Emapalumab. Lopinavir The serum concentration of Emapalumab can be increased when it is combined with Lopinavir. Lorcaserin The metabolism of Lorcaserin can be increased when combined with Emapalumab. Lorlatinib The metabolism of Lorlatinib can be increased when combined with Emapalumab. Lornoxicam The metabolism of Lornoxicam can be increased when combined with Emapalumab. Lorpiprazole The metabolism of Lorpiprazole can be increased when combined with Emapalumab. Losartan The metabolism of Losartan can be increased when combined with Emapalumab. Lovastatin The metabolism of Lovastatin can be increased when combined with Emapalumab. Lumiracoxib The metabolism of Lumiracoxib can be increased when combined with Emapalumab. Lynestrenol The metabolism of Lynestrenol can be increased when combined with Emapalumab. Maftivimab The risk or severity of adverse effects can be increased when Emapalumab is combined with Maftivimab. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Emapalumab. Maprotiline The metabolism of Maprotiline can be increased when combined with Emapalumab. Margetuximab The risk or severity of adverse effects can be increased when Emapalumab is combined with Margetuximab. Mavacamten The metabolism of Mavacamten can be increased when combined with Emapalumab. Measles attenuated The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Emapalumab. Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Emapalumab. Meclizine The metabolism of Meclizine can be increased when combined with Emapalumab. Mefenamic acid The metabolism of Mefenamic acid can be increased when combined with Emapalumab. Melatonin The metabolism of Melatonin can be increased when combined with Emapalumab. Meloxicam The metabolism of Meloxicam can be increased when combined with Emapalumab. Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Emapalumab. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Emapalumab. Meperidine The metabolism of Meperidine can be increased when combined with Emapalumab. Mephenytoin The metabolism of Mephenytoin can be increased when combined with Emapalumab. Mepolizumab The risk or severity of adverse effects can be increased when Mepolizumab is combined with Emapalumab. Meprednisone The risk or severity of adverse effects can be increased when Meprednisone is combined with Emapalumab. Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Emapalumab. Mesoridazine The metabolism of Mesoridazine can be increased when combined with Emapalumab. Mestranol The metabolism of Mestranol can be increased when combined with Emapalumab. Metamfetamine The metabolism of Metamfetamine can be increased when combined with Emapalumab. Methadone The metabolism of Methadone can be increased when combined with Emapalumab. Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Emapalumab. Methotrexate The metabolism of Methotrexate can be increased when combined with Emapalumab. Methotrimeprazine The metabolism of Methotrimeprazine can be increased when combined with Emapalumab. Methoxyflurane The metabolism of Methoxyflurane can be increased when combined with Emapalumab. Methsuximide The metabolism of Methsuximide can be increased when combined with Emapalumab. Methylene blue The metabolism of Methylene blue can be increased when combined with Emapalumab. Methylphenobarbital The metabolism of Methylphenobarbital can be increased when combined with Emapalumab. Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Emapalumab. Methylprednisone The metabolism of Methylprednisone can be increased when combined with Emapalumab. Methyltestosterone The metabolism of Methyltestosterone can be increased when combined with Emapalumab. Methysergide The metabolism of Methysergide can be increased when combined with Emapalumab. Metoclopramide The metabolism of Metoclopramide can be increased when combined with Emapalumab. Metoprolol The metabolism of Metoprolol can be increased when combined with Emapalumab. Metronidazole The metabolism of Metronidazole can be increased when combined with Emapalumab. Mexiletine The metabolism of Mexiletine can be increased when combined with Emapalumab. Mianserin The metabolism of Mianserin can be increased when combined with Emapalumab. Midazolam The metabolism of Midazolam can be increased when combined with Emapalumab. Midostaurin The metabolism of Midostaurin can be increased when combined with Emapalumab. Mifepristone The metabolism of Mifepristone can be increased when combined with Emapalumab. Minaprine The metabolism of Minaprine can be increased when combined with Emapalumab. Mirabegron The metabolism of Mirabegron can be increased when combined with Emapalumab. Mirtazapine The metabolism of Mirtazapine can be increased when combined with Emapalumab. Mirvetuximab The risk or severity of adverse effects can be increased when Mirvetuximab Soravtansine is combined with Emapalumab. Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Emapalumab. Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Emapalumab. Mobocertinib The metabolism of Mobocertinib can be increased when combined with Emapalumab. Moclobemide The metabolism of Moclobemide can be increased when combined with Emapalumab. Modafinil The metabolism of Modafinil can be increased when combined with Emapalumab. COVID-19 Vaccine The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Emapalumab. Modified vaccinia The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Emapalumab. Mogamulizumab The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Emapalumab. Mometasone furoate The risk or severity of adverse effects can be increased when Mometasone furoate is combined with Emapalumab. Monomethyl The risk or severity of adverse effects can be increased when Monomethyl fumarate is combined with Emapalumab. Montelukast The metabolism of Montelukast can be increased when combined with Emapalumab. Morphine The metabolism of Morphine can be increased when combined with Emapalumab. Mosunetuzumab The risk or severity of adverse effects can be increased when Emapalumab is combined with Mosunetuzumab. Mumps antigen The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Emapalumab. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Emapalumab. Mycophenolate The metabolism of Mycophenolate mofetil can be increased when combined with Emapalumab. Mycophenolic The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Emapalumab. Nabilone The metabolism of Nabilone can be increased when combined with Emapalumab. Nabumetone The metabolism of Nabumetone can be increased when combined with Emapalumab. Nadolol The metabolism of Nadolol can be increased when combined with Emapalumab. Naproxen The metabolism of Naproxen can be increased when combined with Emapalumab. Natalizumab The risk or severity of adverse effects can be increased when Emapalumab is combined with Natalizumab. Nateglinide The metabolism of Nateglinide can be increased when combined with Emapalumab. Nebivolol The metabolism of Nebivolol can be increased when combined with Emapalumab. Necitumumab The risk or severity of adverse effects can be increased when Necitumumab is combined with Emapalumab. Nefazodone The metabolism of Nefazodone can be increased when combined with Emapalumab. Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Emapalumab. Neratinib The metabolism of Neratinib can be increased when combined with Emapalumab. Netupitant The metabolism of Netupitant can be increased when combined with Emapalumab. Nevirapine The metabolism of Nevirapine can be increased when combined with Emapalumab. Nicardipine The metabolism of Nicardipine can be increased when combined with Emapalumab. Nicergoline The metabolism of Nicergoline can be increased when combined with Emapalumab. Niclosamide The metabolism of Niclosamide can be increased when combined with Emapalumab. Nicotine The metabolism of Nicotine can be increased when combined with Emapalumab. Nifedipine The metabolism of Nifedipine can be increased when combined with Emapalumab. Nilotinib The metabolism of Nilotinib can be increased when combined with Emapalumab. Nilutamide The metabolism of Nilutamide can be increased when combined with Emapalumab. Nilvadipine The metabolism of Nilvadipine can be increased when combined with Emapalumab. Nintedanib The metabolism of Nintedanib can be increased when combined with Emapalumab. Nisoldipine The metabolism of Nisoldipine can be increased when combined with Emapalumab. Nitrendipine The metabolism of Nitrendipine can be increased when combined with Emapalumab. Nivolumab The risk or severity of adverse effects can be increased when Nivolumab is combined with Emapalumab. Norethisterone The metabolism of Norethisterone can be increased when combined with Emapalumab. Norgestimate The metabolism of Norgestimate can be increased when combined with Emapalumab. Nortriptyline The metabolism of Nortriptyline can be increased when combined with Emapalumab. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Emapalumab. Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Emapalumab. Obinutuzumab The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Emapalumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Emapalumab. Odesivimab The risk or severity of adverse effects can be increased when Emapalumab is combined with Odesivimab. Ofatumumab The risk or severity of adverse effects can be increased when Ofatumumab is combined with Emapalumab. Olanzapine The metabolism of Olanzapine can be increased when combined with Emapalumab. Olaparib The metabolism of Olaparib can be increased when combined with Emapalumab. Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Emapalumab. Oliceridine The metabolism of Oliceridine can be increased when combined with Emapalumab. Olodaterol The metabolism of Olodaterol can be increased when combined with Emapalumab. Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Emapalumab. Ombitasvir The metabolism of Ombitasvir can be increased when combined with Emapalumab. Omeprazole The metabolism of Omeprazole can be increased when combined with Emapalumab. Ondansetron The metabolism of Ondansetron can be increased when combined with Emapalumab. Opium The metabolism of Opium can be increased when combined with Emapalumab. Osilodrostat The metabolism of Osilodrostat can be increased when combined with Emapalumab. Osimertinib The metabolism of Osimertinib can be increased when combined with Emapalumab. Ospemifene The metabolism of Ospemifene can be increased when combined with Emapalumab. Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Emapalumab. Oxprenolol The metabolism of Oxprenolol can be increased when combined with Emapalumab. Oxtriphylline The metabolism of Oxtriphylline can be increased when combined with Emapalumab. Oxybutynin The metabolism of Oxybutynin can be increased when combined with Emapalumab. Oxycodone The metabolism of Oxycodone can be increased when combined with Emapalumab. Oxymorphone The metabolism of Oxymorphone can be increased when combined with Emapalumab. Ozanimod The risk or severity of adverse effects can be increased when Ozanimod is combined with Emapalumab. Paclitaxel The metabolism of Paclitaxel can be increased when combined with Emapalumab. Palbociclib The metabolism of Palbociclib can be increased when combined with Emapalumab. Paliperidone The metabolism of Paliperidone can be increased when combined with Emapalumab. Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Emapalumab. Palonosetron The metabolism of Palonosetron can be increased when combined with Emapalumab. Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Emapalumab. Panobinostat The metabolism of Panobinostat can be increased when combined with Emapalumab. Pantoprazole The metabolism of Pantoprazole can be increased when combined with Emapalumab. Paramethadione The metabolism of Paramethadione can be increased when combined with Emapalumab. Parecoxib The metabolism of Parecoxib can be increased when combined with Emapalumab. Paritaprevir The metabolism of Paritaprevir can be increased when combined with Emapalumab. Paroxetine The metabolism of Paroxetine can be increased when combined with Emapalumab. Pazopanib The metabolism of Pazopanib can be increased when combined with Emapalumab. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Emapalumab. Pegcetacoplan The risk or severity of adverse effects can be increased when Emapalumab is combined with Pegcetacoplan. Peginterferon The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Emapalumab. Peginterferon The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Emapalumab. Peginterferon The risk or severity of adverse effects can be increased when Peginterferon beta-1a is combined with Emapalumab. Pembrolizumab The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Emapalumab. Pemetrexed The metabolism of Pemetrexed can be increased when combined with Emapalumab. Penbutolol The metabolism of Penbutolol can be increased when combined with Emapalumab. Penciclovir The metabolism of Penciclovir can be increased when combined with Emapalumab. Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Emapalumab. Pentamidine The metabolism of Pentamidine can be increased when combined with Emapalumab. Pentobarbital The metabolism of Pentobarbital can be increased when combined with Emapalumab. Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Emapalumab. Pentoxifylline The metabolism of Pentoxifylline can be increased when combined with Emapalumab. Perampanel The metabolism of Perampanel can be increased when combined with Emapalumab. Perhexiline The metabolism of Perhexiline can be increased when combined with Emapalumab. Perphenazine The metabolism of Perphenazine can be increased when combined with Emapalumab. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Emapalumab. Pertuzumab The risk or severity of adverse effects can be increased when Pertuzumab is combined with Emapalumab. Pexidartinib The metabolism of Pexidartinib can be increased when combined with Emapalumab. Phenformin The metabolism of Phenformin can be increased when combined with Emapalumab. Phenobarbital The metabolism of Phenobarbital can be increased when combined with Emapalumab. Phenprocoumon The metabolism of Phenprocoumon can be increased when combined with Emapalumab. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Emapalumab. Phenylbutazone The metabolism of Phenylbutazone can be increased when combined with Emapalumab. Phenytoin The metabolism of Phenytoin can be increased when combined with Emapalumab. Pimavanserin The metabolism of Pimavanserin can be increased when combined with Emapalumab. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Emapalumab. Pimozide The metabolism of Pimozide can be increased when combined with Emapalumab. Pindolol The metabolism of Pindolol can be increased when combined with Emapalumab. Pioglitazone The metabolism of Pioglitazone can be increased when combined with Emapalumab. Piperaquine The metabolism of Piperaquine can be increased when combined with Emapalumab. Piperazine The metabolism of Piperazine can be increased when combined with Emapalumab. Pipotiazine The metabolism of Pipotiazine can be increased when combined with Emapalumab. Pirfenidone The metabolism of Pirfenidone can be increased when combined with Emapalumab. Piroxicam The metabolism of Piroxicam can be increased when combined with Emapalumab. Pitavastatin The metabolism of Pitavastatin can be increased when combined with Emapalumab. Pitolisant The metabolism of Pitolisant can be increased when combined with Emapalumab. Polatuzumab The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Emapalumab. Polyestradiol Polyestradiol phosphate may increase the thrombogenic activities of Emapalumab. Pomalidomide The metabolism of Pomalidomide can be increased when combined with Emapalumab. Ponatinib The metabolism of Ponatinib can be increased when combined with Emapalumab. Ponesimod The metabolism of Ponesimod can be increased when combined with Emapalumab. Practolol The metabolism of Practolol can be increased when combined with Emapalumab. Pralatrexate The risk or severity of adverse effects can be increased when Pralatrexate is combined with Emapalumab. Prasugrel The metabolism of Prasugrel can be increased when combined with Emapalumab. Praziquantel The metabolism of Praziquantel can be increased when combined with Emapalumab. Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Emapalumab. Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Emapalumab. Pretomanid The metabolism of Pretomanid can be increased when combined with Emapalumab. Primaquine The metabolism of Primaquine can be increased when combined with Emapalumab. Primidone The metabolism of Primidone can be increased when combined with Emapalumab. Procainamide The metabolism of Procainamide can be increased when combined with Emapalumab. Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Emapalumab. Prochlorperazine The metabolism of Prochlorperazine can be increased when combined with Emapalumab. Progesterone The metabolism of Progesterone can be increased when combined with Emapalumab. Proguanil The metabolism of Proguanil can be increased when combined with Emapalumab. Promazine The metabolism of Promazine can be increased when combined with Emapalumab. Promethazine The metabolism of Promethazine can be increased when combined with Emapalumab. Propafenone The metabolism of Propafenone can be increased when combined with Emapalumab. Propofol The metabolism of Propofol can be increased when combined with Emapalumab. Propranolol The metabolism of Propranolol can be increased when combined with Emapalumab. Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Emapalumab. Quazepam The metabolism of Quazepam can be increased when combined with Emapalumab. Quetiapine The metabolism of Quetiapine can be increased when combined with Emapalumab. Quinestrol Quinestrol may increase the thrombogenic activities of Emapalumab. Quinidine The metabolism of Quinidine can be increased when combined with Emapalumab. Quinine The metabolism of Quinine can be increased when combined with Emapalumab. Rabeprazole The metabolism of Rabeprazole can be increased when combined with Emapalumab. Rabies immune The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Emapalumab. R antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Emapalumab. R antigen, B The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Emapalumab. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Emapalumab. Ramelteon The metabolism of Ramelteon can be increased when combined with Emapalumab. Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Emapalumab. Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Emapalumab. Ranitidine The metabolism of Ranitidine can be increased when combined with Emapalumab. Ranolazine The metabolism of Ranolazine can be increased when combined with Emapalumab. Rasagiline The metabolism of Rasagiline can be increased when combined with Emapalumab. Ravulizumab The risk or severity of adverse effects can be increased when Ravulizumab is combined with Emapalumab. Raxibacumab The risk or severity of adverse effects can be increased when Raxibacumab is combined with Emapalumab. Regorafenib The metabolism of Regorafenib can be increased when combined with Emapalumab. Relugolix The metabolism of Relugolix can be increased when combined with Emapalumab. Remoxipride The metabolism of Remoxipride can be increased when combined with Emapalumab. Repaglinide The metabolism of Repaglinide can be increased when combined with Emapalumab. Reslizumab The risk or severity of adverse effects can be increased when Reslizumab is combined with Emapalumab. Revefenacin The metabolism of Revefenacin can be increased when combined with Emapalumab. Ribociclib The metabolism of Ribociclib can be increased when combined with Emapalumab. Rilonacept The risk or severity of adverse effects can be increased when Rilonacept is combined with Emapalumab. Rilpivirine The metabolism of Rilpivirine can be increased when combined with Emapalumab. Riluzole The metabolism of Riluzole can be increased when combined with Emapalumab. Riociguat The metabolism of Riociguat can be increased when combined with Emapalumab. Risankizumab The risk or severity of adverse effects can be increased when Emapalumab is combined with Risankizumab. Risperidone The metabolism of Risperidone can be increased when combined with Emapalumab. Ritonavir The metabolism of Ritonavir can be increased when combined with Emapalumab. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Emapalumab. Rivaroxaban The metabolism of Rivaroxaban can be increased when combined with Emapalumab. Rofecoxib The metabolism of Rofecoxib can be increased when combined with Emapalumab. Roflumilast Roflumilast may increase the immunosuppressive activities of Emapalumab. Romidepsin The metabolism of Romidepsin can be increased when combined with Emapalumab. Romosozumab The risk or severity of adverse effects can be increased when Romosozumab is combined with Emapalumab. Ropeginterferon The risk or severity of adverse effects can be increased when Emapalumab is combined with Ropeginterferon alfa-2b. Ropinirole The metabolism of Ropinirole can be increased when combined with Emapalumab. Ropivacaine The metabolism of Ropivacaine can be increased when combined with Emapalumab. Rosiglitazone The metabolism of Rosiglitazone can be increased when combined with Emapalumab. Rosuvastatin The metabolism of Rosuvastatin can be increased when combined with Emapalumab. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Emapalumab. Rotigotine The metabolism of Rotigotine can be increased when combined with Emapalumab. Roxadustat The metabolism of Roxadustat can be increased when combined with Emapalumab. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Emapalumab. Rucaparib The metabolism of Rucaparib can be increased when combined with Emapalumab. Rupatadine The metabolism of Rupatadine can be increased when combined with Emapalumab. Ruxolitinib The metabolism of Ruxolitinib can be increased when combined with Emapalumab. Sacituzumab The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Emapalumab. Salicylic acid The metabolism of Salicylic acid can be increased when combined with Emapalumab. Salmeterol The metabolism of Salmeterol can be increased when combined with Emapalumab. Saquinavir The metabolism of Saquinavir can be increased when combined with Emapalumab. Sarilumab The risk or severity of adverse effects can be increased when Sarilumab is combined with Emapalumab. Satralizumab The risk or severity of adverse effects can be increased when Emapalumab is combined with Satralizumab. Saxagliptin The metabolism of Saxagliptin can be increased when combined with Emapalumab. Secukinumab The risk or severity of adverse effects can be increased when Secukinumab is combined with Emapalumab. Selegiline The metabolism of Selegiline can be increased when combined with Emapalumab. Selexipag The metabolism of Selexipag can be increased when combined with Emapalumab. Selumetinib The metabolism of Selumetinib can be increased when combined with Emapalumab. Sertindole The metabolism of Sertindole can be increased when combined with Emapalumab. Sertraline The metabolism of Sertraline can be increased when combined with Emapalumab. Sevoflurane The metabolism of Sevoflurane can be increased when combined with Emapalumab. Sildenafil The metabolism of Sildenafil can be increased when combined with Emapalumab. Siltuximab The risk or severity of adverse effects can be increased when Siltuximab is combined with Emapalumab. Simvastatin The metabolism of Simvastatin can be increased when combined with Emapalumab. Siponimod The metabolism of Siponimod can be increased when combined with Emapalumab. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Emapalumab. Sirolimus The metabolism of Sirolimus can be increased when combined with Emapalumab. Sitagliptin The metabolism of Sitagliptin can be increased when combined with Emapalumab. Sitaxentan The metabolism of Sitaxentan can be increased when combined with Emapalumab. Smallpox The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Emapalumab. Solifenacin The metabolism of Solifenacin can be increased when combined with Emapalumab. Sonidegib The metabolism of Sonidegib can be increased when combined with Emapalumab. Sorafenib The metabolism of Sorafenib can be increased when combined with Emapalumab. Sotalol The metabolism of Sotalol can be increased when combined with Emapalumab. Sotrovimab The risk or severity of adverse effects can be increased when Emapalumab is combined with Sotrovimab. Spesolimab The risk or severity of adverse effects can be increased when Emapalumab is combined with Spesolimab. St. John’s Wort The metabolism of St. John’s Wort can be increased when combined with Emapalumab. Stiripentol The metabolism of Stiripentol can be increased when combined with Emapalumab. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Emapalumab. Sulesomab The risk or severity of adverse effects can be increased when Sulesomab is combined with Emapalumab. Sulfadiazine The metabolism of Sulfadiazine can be increased when combined with Emapalumab. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Emapalumab. Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Emapalumab. Sunitinib The metabolism of Sunitinib can be increased when combined with Emapalumab. Sutimlimab The risk or severity of adverse effects can be increased when Emapalumab is combined with Sutimlimab. Suvorexant The metabolism of Suvorexant can be increased when combined with Emapalumab. Tacrine The metabolism of Tacrine can be increased when combined with Emapalumab. Tacrolimus Tacrolimus may increase the immunosuppressive activities of Emapalumab. Tadalafil The metabolism of Tadalafil can be increased when combined with Emapalumab. Tafasitamab The risk or severity of adverse effects can be increased when Emapalumab is combined with Tafasitamab. Tafenoquine The metabolism of Tafenoquine can be increased when combined with Emapalumab. Tamoxifen The metabolism of Tamoxifen can be increased when combined with Emapalumab. Tamsulosin The metabolism of Tamsulosin can be increased when combined with Emapalumab. Tasimelteon The metabolism of Tasimelteon can be increased when combined with Emapalumab. Tazarotene The metabolism of Tazarotene can be increased when combined with Emapalumab. Tazemetostat The metabolism of Tazemetostat can be increased when combined with Emapalumab. Tegafur The metabolism of Tegafur can be increased when combined with Emapalumab. Tegafur-uracil The metabolism of Tegafur-uracil can be increased when combined with Emapalumab. Tegaserod The metabolism of Tegaserod can be increased when combined with Emapalumab. Telaprevir The metabolism of Telaprevir can be increased when combined with Emapalumab. Telithromycin The metabolism of Telithromycin can be increased when combined with Emapalumab. Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Emapalumab. Temsirolimus The metabolism of Temsirolimus can be increased when combined with Emapalumab. Teniposide The metabolism of Teniposide can be increased when combined with Emapalumab. Tenofovir The metabolism of Tenofovir alafenamide can be increased when combined with Emapalumab. Tenoxicam The metabolism of Tenoxicam can be increased when combined with Emapalumab. Teplizumab The risk or severity of adverse effects can be increased when Teplizumab is combined with Emapalumab. Teprotumumab The risk or severity of adverse effects can be increased when Teprotumumab is combined with Emapalumab. Terbinafine The metabolism of Terbinafine can be increased when combined with Emapalumab. Terfenadine The metabolism of Terfenadine can be increased when combined with Emapalumab. Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Emapalumab. Testosterone The metabolism of Testosterone can be increased when combined with Emapalumab. Testosterone The metabolism of Testosterone cypionate can be increased when combined with Emapalumab. Testosterone The metabolism of Testosterone enanthate can be increased when combined with Emapalumab. Tetanus The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Emapalumab. Tetrabenazine The metabolism of Tetrabenazine can be increased when combined with Emapalumab. Tezacaftor The metabolism of Tezacaftor can be increased when combined with Emapalumab. Tezepelumab The risk or severity of adverse effects can be increased when Emapalumab is combined with Tezepelumab. Thalidomide The metabolism of Thalidomide can be increased when combined with Emapalumab. Theophylline The metabolism of Theophylline can be increased when combined with Emapalumab. Thiabendazole The metabolism of Thiabendazole can be increased when combined with Emapalumab. Thiamylal The metabolism of Thiamylal can be increased when combined with Emapalumab. Thiopental The metabolism of Thiopental can be increased when combined with Emapalumab. Thioridazine The metabolism of Thioridazine can be increased when combined with Emapalumab. Thiotepa The metabolism of Thiotepa can be increased when combined with Emapalumab. Thiothixene The metabolism of Thiothixene can be increased when combined with Emapalumab. Tibolone Tibolone may increase the thrombogenic activities of Emapalumab. Ticagrelor The metabolism of Ticagrelor can be increased when combined with Emapalumab. Tick-borne The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Emapalumab. Ticlopidine The metabolism of Ticlopidine can be increased when combined with Emapalumab. Tildrakizumab The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Emapalumab. Timolol The metabolism of Timolol can be increased when combined with Emapalumab. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Emapalumab. Tiotropium The metabolism of Tiotropium can be increased when combined with Emapalumab. Tipranavir The metabolism of Tipranavir can be increased when combined with Emapalumab. Tisotumab The risk or severity of adverse effects can be increased when Emapalumab is combined with Tisotumab vedotin. Tixagevimab The risk or severity of adverse effects can be increased when Emapalumab is combined with Tixagevimab. Tixocortol The risk or severity of adverse effects can be increased when Tixocortol is combined with Emapalumab. Tizanidine The metabolism of Tizanidine can be increased when combined with Emapalumab. Tocainide The metabolism of Tocainide can be increased when combined with Emapalumab. Tocilizumab The risk or severity of adverse effects can be increased when Tocilizumab is combined with Emapalumab. Tofacitinib Emapalumab may increase the immunosuppressive activities of Tofacitinib. Tolazamide The metabolism of Tolazamide can be increased when combined with Emapalumab. Tolbutamide The metabolism of Tolbutamide can be increased when combined with Emapalumab. Tolterodine The metabolism of Tolterodine can be increased when combined with Emapalumab. Tolvaptan The metabolism of Tolvaptan can be increased when combined with Emapalumab. Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Emapalumab. Torasemide The metabolism of Torasemide can be increased when combined with Emapalumab. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Emapalumab. Trabectedin The metabolism of Trabectedin can be increased when combined with Emapalumab. Tralokinumab The risk or severity of adverse effects can be increased when Tralokinumab is combined with Emapalumab. Tramadol The metabolism of Tramadol can be increased when combined with Emapalumab. Trastuzumab Trastuzumab may increase the neutropenic activities of Emapalumab. Trastuzumab The risk or severity of adverse effects can be increased when Emapalumab is combined with Trastuzumab deruxtecan. Trastuzumab The metabolism of Trastuzumab emtansine can be increased when combined with Emapalumab. Trazodone The metabolism of Trazodone can be increased when combined with Emapalumab. Tremelimumab The risk or severity of adverse effects can be increased when Tremelimumab is combined with Emapalumab. Treprostinil The metabolism of Treprostinil can be increased when combined with Emapalumab. Tretinoin The metabolism of Tretinoin can be increased when combined with Emapalumab. Triamcinolone The metabolism of Triamcinolone can be increased when combined with Emapalumab. Triamterene The metabolism of Triamterene can be increased when combined with Emapalumab. Triazolam The metabolism of Triazolam can be increased when combined with Emapalumab. Triclabendazole The metabolism of Triclabendazole can be increased when combined with Emapalumab. Trifluoperazine The metabolism of Trifluoperazine can be increased when combined with Emapalumab. Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Emapalumab. Trilostane The risk or severity of adverse effects can be increased when Trilostane is combined with Emapalumab. Trimethadione The metabolism of Trimethadione can be increased when combined with Emapalumab. Trimethoprim The metabolism of Trimethoprim can be increased when combined with Emapalumab. Trimipramine The metabolism of Trimipramine can be increased when combined with Emapalumab. Troglitazone The metabolism of Troglitazone can be increased when combined with Emapalumab. Tucatinib The metabolism of Tucatinib can be increased when combined with Emapalumab. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Emapalumab. Typhoid Vaccine The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Emapalumab. Typhoid Vi The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Emapalumab. Udenafil The metabolism of Udenafil can be increased when combined with Emapalumab. Umeclidinium The metabolism of Umeclidinium can be increased when combined with Emapalumab. Upadacitinib The risk or severity of adverse effects can be increased when Emapalumab is combined with Upadacitinib. Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Emapalumab. Valentine The metabolism of Valbenazine can be increased when combined with Emapalumab. Valdecoxib The metabolism of Valdecoxib can be increased when combined with Emapalumab. Valproic acid The metabolism of Valproic acid can be increased when combined with Emapalumab. Valsartan The metabolism of Valsartan can be increased when combined with Emapalumab. Vandetanib The metabolism of Vandetanib can be increased when combined with Emapalumab. Vardenafil The metabolism of Vardenafil can be increased when combined with Emapalumab. Pregnancy and Lactation US FDA pregnancy category: Not assigned. Pregnancy The manufacturer makes no recommendation regarding use during pregnancy. There are no available data on the use of this drug in pregnant women to inform a drug-associated risk of adverse developmental outcomes. In animal studies, a murine surrogate anti-mouse antibody administered to pregnant mice throughout gestation crossed the placental barrier, and no fetal harm was observed. Lactation Safety has not been established. Excreted into human milk: Unknown Excreted into animal milk: Data not available The effects in the nursing infant are unknown. Available data suggest that only limited amounts of therapeutic antibodies are found in breast milk and they do not enter the neonatal and infant circulations in substantial amounts. How should this medicine be used? Emapalumab-lzsg comes as a liquid to be injected into a vein over 1 hour by a doctor or nurse in a hospital or medical facility. It is usually given 2 times per week, every 3 or 4 days, for as long as your doctor recommends that you receive treatment. Your doctor may start you on a low dose of emapalumab-lzsg injection and gradually increase your dose, not more than once every 3 days. Emapalumab-lzsg injection may cause a severe reaction during or shortly after the infusion of the medication. A doctor or nurse will monitor you carefully while you are receiving the medication. If you experience any of the following symptoms, tell your doctor immediately: skin redness, itching, fever, rash, excessive sweating, chills, nausea, vomiting, lightheadedness, dizziness, chest pain, or shortness of breath. Your doctor or pharmacist will give you the manufacturer’s patient information sheet (Medication Guide) when you begin treatment with emapalumab-lzsg injection and each time you receive the medication. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer’s website to obtain the Medication Guide. What special precautions should I follow? Before receiving emapalumab-lzsg injection, tell your doctor and pharmacist if you are allergic to emapalumab-lzsg, any other medications, or any of the ingredients in emapalumab-lzsg injection. Ask your pharmacist or check the Medication Guide for a list of the ingredients. tell your doctor if you have or have ever had any medical condition. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while receiving emapalumab-lzsg injection, call your doctor. you should know that emapalumab-lzsg injection may decrease your ability to fight infection from bacteria, viruses, and fungi and increase the risk that you will get a serious or life-threatening infection. Tell your doctor if you often get any type of infection or if you have or think you may have any type of infection now. This includes minor infections (such as open cuts or sores), infections that come and go (such as herpes or cold sores), and chronic infections that do not go away. If you experience any of the following symptoms during or shortly after your treatment with emapalumab-lzsg injection, call your doctor immediately: fever, sweats, or chills; muscle aches; cough; bloody mucus; shortness of breath; sore throat or difficulty swallowing; warm, red, or painful skin or sores on your body; diarrhea; stomach pain; frequent, urgent, or painful urination; or other signs of infection. you should know that receiving emapalumab-lzsg injection increases the risk that you will develop tuberculosis (TB; a serious lung infection), especially if you are already infected with TB but do not have any symptoms of the disease. Tell your doctor if you have or have ever had TB, if you have lived in a country where TB is common, or if you have been around someone who has TB. Your doctor will check you for TB before starting treatment with emapalumab-lzsg injection and may treat you for TB if you have a history of TB or have active TB. If you have any of the following symptoms of TB or if you develop any of these symptoms during your treatment, call your doctor immediately: cough, coughing up blood or mucus, weakness or tiredness, weight loss, loss of appetite, chills, fever, or night sweats. do not have any vaccinations without talking to your doctor during your treatment with emapalumab-lzsg injection and for at least 4 weeks after your final dose. References https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761107lbl.pdf https://www.fda.gov/drugs/fda-approves-emapalumab-hemophagocytic-lymphohistiocytosis https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-specifically-patients-rare-and-life-threatening-type-immune-disease https://www.ncbi.nlm.nih.gov/books/NBK547952/ https://www.mayoclinic.org/drugs-supplements/emapalumab-lzsg-intravenous-route/side-effects/drg-20452356 https://www.drugs.com/mtm/emapalumab.html https://go.drugbank.com/drugs/DB14724 https://pubchem.ncbi.nlm.nih.gov/substance/318164814 https://www.webmd.com/drugs/2/drug-176562/emapalumab-lzsg-intravenous/details/list-contraindications Show More